Trial site
Sanatorio Parque
Rosario, S2001, ArgentinaNot linked to an institution yet
- 14running trials
- 4closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 315 trials
- Phase 1/21 trial
- Phase 21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Recruiting5 trials
- Completed4 trials
- Enrolling by invitation1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Janssen Research & Development, LLC4 trials
- Daiichi Sankyo3 trials
- Pfizer3 trials
- Seagen, a wholly owned subsidiary of Pfizer2 trials
- United Therapeutics2 trials
- and 4 more
Running trials
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966· Phase 1/2· Daiichi Sankyo· Source
Recruiting
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428· Phase 2· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: Gaston Martinengo, Site 0216
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· Phase 3· Daiichi Sankyo· Source
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source
Contact: Gaston Martinengo, Site 007-439
Enrolling by invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186· Phase 3· United Therapeutics· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error